Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.

CD86 ICAM-1 Natural killer (NK) cells T cells epstein barr virus (EBV) human T lymphotropic virus type 1 (HTLV-1) ikaros (IKZF1). interferon regulatory factor 4 (IRF4) major histocompatibility complex class I (MHC-I) pomalidomide

Journal

Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
Historique:
received: 15 06 2018
revised: 17 10 2018
accepted: 04 11 2018
entrez: 5 2 2019
pubmed: 5 2 2019
medline: 5 2 2019
Statut: epublish

Résumé

Most chronic viruses evade T-cell and natural killer (NK) immunity through downregulation of immune surface markers. Previously we showed that Pomalidomide (Pom) increases surface expression of major histocompatibility complex class I (MHC-I) in Kaposi sarcoma-associated herpesvirus-infected latent and lytic cells and restores ICAM-1 and B7-2 in latent cells. We explored the ability of Pom to increase immune surface marker expression in cells infected by other chronic viruses, including human T-cell leukemia virus type-1 (HTLV-1), Epstein-Barr virus (EBV), human papilloma virus (HPV), Merkel cell polyoma virus (MCV), and human immunodeficiency virus type-1 (HIV-1). Pom increased MHC-1, ICAM-1, and B7-2/CD86 in immortalized T-cell lines productively infected with HTLV-1 and also significantly increased their susceptibility to NK cell-mediated cytotoxicity. Pom enhancement of MHC-I and ICAM-1 in primary cells infected with HTLV-1 was abrogated by knockout of HTLV-1

Identifiants

pubmed: 30713808
doi: 10.1080/2162402X.2018.1546544
pii: 1546544
pmc: PMC6343774
doi:

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e1546544

Références

J Immunol. 1999 Oct 15;163(8):4207-12
pubmed: 10510357
J Clin Oncol. 2000 Jul;18(13):2593-602
pubmed: 10893291
Hum Immunol. 2000 Aug;61(8):721-8
pubmed: 10980383
Immunity. 2000 Sep;13(3):365-74
pubmed: 11021534
AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1777-81
pubmed: 11080826
J Virol. 2001 Jul;75(13):6086-94
pubmed: 11390610
Nature. 2001 Sep 13;413(6852):165-71
pubmed: 11557981
J Immunol. 2001 Nov 1;167(9):5193-201
pubmed: 11673532
Nat Rev Immunol. 2001 Oct;1(1):41-9
pubmed: 11905813
J Immunol Methods. 2002 Sep 15;267(2):157-63
pubmed: 12165437
J Virol. 2003 Mar;77(5):3041-9
pubmed: 12584329
J Immunol. 1992 Aug 15;149(4):1115-23
pubmed: 1380031
Immunology. 2003 Oct;110(2):163-9
pubmed: 14511229
J Interferon Cytokine Res. 2005 Oct;25(10):604-16
pubmed: 16241859
J Virol. 2005 Dec;79(24):15099-106
pubmed: 16306581
Int J Cancer. 2006 Nov 1;119(9):2105-12
pubmed: 16823848
J Virol. 2007 Sep;81(18):9707-17
pubmed: 17609265
Eur J Cell Biol. 2007 Oct;86(10):581-9
pubmed: 17651861
Blood. 2009 Apr 16;113(16):3726-34
pubmed: 18791162
Cancer Immunol Immunother. 2009 Jul;58(7):1033-45
pubmed: 19009291
PLoS Pathog. 2009 Jan;5(1):e1000255
pubmed: 19119421
Blood. 2009 Sep 24;114(13):2667-77
pubmed: 19553639
J Immunol. 1990 Jun 15;144(12):4579-86
pubmed: 1972160
J Virol. 2010 Jul;84(14):7064-72
pubmed: 20444890
Blood. 2010 Nov 11;116(19):3809-17
pubmed: 20647569
Virology. 2010 Nov 10;407(1):137-42
pubmed: 20813390
Leuk Lymphoma. 2011 Apr;52(4):560-6
pubmed: 21338284
AIDS. 2011 Mar 27;25(6):878-80
pubmed: 21412067
J Immunol. 1990 Jun 15;144(12):4788-93
pubmed: 2161880
Biochem Biophys Res Commun. 2011 Jun 17;409(4):792-8
pubmed: 21621523
Blood. 2011 Nov 3;118(18):4771-9
pubmed: 21860026
Cancer Res. 2011 Oct 15;71(20):6410-8
pubmed: 21900395
Viruses. 2011 Jun;3(6):861-85
pubmed: 21994758
Front Microbiol. 2012 Mar 05;3:44
pubmed: 22403573
Leukemia. 2012 Nov;26(11):2326-35
pubmed: 22552008
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Aug;20(4):1039-41
pubmed: 22931680
Front Microbiol. 2012 Dec 11;3:400
pubmed: 23248621
JAMA Dermatol. 2013 Nov;149(11):1319-22
pubmed: 24080749
Br J Haematol. 2014 Mar;164(6):811-21
pubmed: 24328678
Cell Rep. 2013 Dec 26;5(6):1489-98
pubmed: 24360958
J Virol. 1989 Jan;63(1):445-9
pubmed: 2462063
Cancer Immunol Res. 2014 Nov;2(11):1071-9
pubmed: 25116754
PLoS One. 2014 Sep 10;9(9):e106788
pubmed: 25207815
PLoS Pathog. 2014 Nov 06;10(11):e1004454
pubmed: 25375128
Virus Genes. 1989 Nov;3(2):141-52
pubmed: 2559541
Hum Vaccin Immunother. 2014;10(11):3111-6
pubmed: 25625924
J Immunol. 1985 Mar;134(3):1623-30
pubmed: 2578514
J Virol. 2015 Jul;89(14):7248-61
pubmed: 25948739
Blood. 2015 Aug 6;126(6):779-89
pubmed: 26002965
Virology. 2015 Oct;484:22-32
pubmed: 26057149
PLoS Pathog. 2015 Jun 11;11(6):e1004906
pubmed: 26067064
Oncogene. 2016 Apr 7;35(14):1797-810
pubmed: 26119939
Curr Cancer Drug Targets. 2015;15(6):452-62
pubmed: 26282545
Blood Cancer J. 2015 Oct 02;5:e354
pubmed: 26430725
J Virol. 2015 Oct 14;90(1):356-67
pubmed: 26468525
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
Clin Cancer Res. 2016 Oct 1;22(19):4901-4912
pubmed: 27297582
AIDS Res Hum Retroviruses. 2017 Jan;33(1):1-10
pubmed: 27405442
J Mol Med (Berl). 2016 Dec;94(12):1327-1334
pubmed: 27492707
J Clin Oncol. 2016 Dec;34(34):4086-4093
pubmed: 27621400
J Exp Med. 2016 Sep 19;213(10):2065-80
pubmed: 27621419
Arch Pharm Res. 2016 Nov;39(11):1577-1587
pubmed: 27770382
J Clin Oncol. 2016 Dec;34(34):4125-4131
pubmed: 27863194
Virus Res. 2017 Mar 2;231:21-33
pubmed: 27890631
Oncotarget. 2017 May 17;8(31):50342-50358
pubmed: 28881567
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
J Hematol Oncol. 2018 Jan 12;11(1):8
pubmed: 29329556
PLoS Pathog. 2018 Jan 22;14(1):e1006868
pubmed: 29357389
Science. 1985 Aug 9;229(4713):563-6
pubmed: 2992081
Blood. 2018 Aug 9;132(6):577-586
pubmed: 29954751
Cancer Immunol Res. 2018 Oct;6(10):1129-1135
pubmed: 30194084
J Exp Med. 1988 Feb 1;167(2):288-99
pubmed: 3279151
Int J Cancer. 1984 Aug 15;34(2):221-8
pubmed: 6088403
Immunogenetics. 1983;17(2):133-40
pubmed: 6186604
Science. 1983 Feb 18;219(4586):856-9
pubmed: 6600519
Proc Natl Acad Sci U S A. 1983 Sep;80(17):5402-6
pubmed: 6604273
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
pubmed: 7513432
Int J Cancer. 1995 Jan 3;60(1):100-7
pubmed: 7814141
Annu Rev Immunol. 1996;14:233-58
pubmed: 8717514
J Exp Med. 1997 Apr 7;185(7):1295-305
pubmed: 9104816
Immunity. 1997 Oct;7(4):549-57
pubmed: 9354475
EMBO J. 1998 May 15;17(10):2777-89
pubmed: 9582271

Auteurs

David A Davis (DA)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Prabha Shrestha (P)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Ashley I Aisabor (AI)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Alexandra Stream (A)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Veronica Galli (V)

Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Cynthia A Pise-Masison (CA)

Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Takanobu Tagawa (T)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Joseph M Ziegelbauer (JM)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Genoveffa Franchini (G)

Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Robert Yarchoan (R)

HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Classifications MeSH